Latest Announcements

Investor Announcement, Alzheimer's Disease

Prana Announces Safety Outcomes of Alzheimer’s IMAGINE Extension Trial

Prana Biotechnology has today announced the safety outcomes of the IMAGINE Extension study in patients with Alzheimer’s disease. A 250mg dose of PBT2 was safe and well tolerated over a 2 year period. The independent Data Safety Monitoring Board did not identify any safety concerns related to PBT2.


Investor Announcement, Huntington's Disease

Prana receives $6.8 million R&D Tax Incentive Refund

Prana Biotechnology Limited has today announced that it has received a $6.8 million cash refund under the Australian Government’s R&D Tax Incentive Scheme.


Movement disorders expert Professor Ira Shoulson joins Prana Biotechnology's Board of Directors

Email Newsletter

Receive regular updates from Prana Biotechnology by entering your details below and clicking "Subscribe"